Phenoxy Carboxylic Acid Compounds for Dual PPAR Metabolic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metabolic diseases such as diabetes mellitus and non-alcoholic steatohepatitis (NASH) are limited, often accompanied by side effects and lack targeted efficacy, with no approved drugs for NASH and significant complications posing health risks.
Innovation Solution
Development of phenoxy carboxylic acid compounds with glycolipid metabolism-regulating and anti-inflammatory/antioxidant activities, formulated into pharmaceutical compositions for oral, parenteral, topical, or rectal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs for diabetes mellitus are used, then blood glucose control is achieved, but weight gain and side effects occur
Solution Approach 1:
The patent modifies the molecular structure of phenoxy carboxylic acid compounds by changing parameters such as substituting hydrogen atoms with halogen atoms (fluorine, chlorine, bromine, iodine) at specific positions (R3-R6), and adjusting alkyl chain lengths and substituents. These structural parameter changes optimize the compounds' binding affinity to PPARα/γ receptors while improving metabolic profile, achieving effective blood glucose control without weight gain and reducing side effects.
Solution Approach 2:
The patent creates composite molecular structures by combining phenoxy carboxylic acid core with various substituent groups (halogenated phenyl rings, alkyl chains, carboxylic acid groups). This composite approach allows the compound to simultaneously activate PPARα and PPARγ receptors with balanced agonist activity, achieving effective glycemic control while avoiding the harmful effects of conventional monotherapies.
2Reliability
If existing treatments for NASH are used, then some metabolic regulation is achieved, but no approved targeted drug exists and liver fibrosis progression continues
Solution Approach 1:
The phenoxy carboxylic acid compounds exhibit multi-functionality by simultaneously activating PPARα and PPARγ receptors, providing broad metabolic regulation effects that cover glucose control, lipid metabolism, and anti-inflammatory actions. This universal mechanism makes the compounds suitable for treating NASH and its metabolic complications with a single agent, achieving targeted efficacy that current separate treatments cannot provide.
Solution Approach 2:
The patent optimizes the molecular parameters of the compounds, particularly the halogen substitution patterns and alkyl chain lengths, to enhance selective binding to PPARα/γ receptors. This precise parameter optimization ensures high affinity and specificity for the target receptors, enabling effective treatment of NASH with reduced off-target effects compared to conventional non-specific metabolic regulators.
3Reliability
If current diabetes medications are used, then glycemic control is achieved, but gradual decline in drug efficacy occurs
Solution Approach 1:
The patent introduces halogen atoms at specific positions in the phenoxy carboxylic acid structure, which fundamentally changes the binding characteristics and pharmacokinetic properties of the compound. These parameter changes result in improved metabolic stability and sustained receptor activation, preventing the gradual efficacy decline observed with conventional drugs while maintaining effective glycemic control over extended periods.
Data Source
AI summary
A phenoxy carboxylic acid compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; a pharmaceutical composition comprising the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof; and a medicinal use of the compound, its pharmaceutically acceptable salt or ester, stereoisomer, prodrug, hydrate, solvate or crystal form, or metabolite form thereof, or any combination or mixture thereof, for preventing and/or treatment of a metabolic disease (e.g., metabolic syndrome, non-alcoholic fatty liver disease, and/or diabetes mellitus).